TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15845719

Group type: EXPERIMENTAL
Intervention: Preoperative anxiety measurement
Number of subjects: 1389

Group type: COMPARATOR
Intervention: Established predictors of PONV (sex, age, smoking, history of PONV or motion sickness, surgery type, anesthetic technique)
Number of subjects: 1389
Study: 12851867

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Desipramine (DES)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Education (EDU)
Number of subjects: 431
Study: 10098341

Group type: EXPERIMENTAL
Intervention: Inflammatory bowel disease (IBD) patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coeliac disease (CD) patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study: 9082344

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 1000 ml 0.16 M NaCl at 16.7 ml/min for 1 hour (induced hypervolemia)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard conditions (before infusion)
Number of subjects: 24
Study: 2049965

Group type: EXPERIMENTAL
Intervention: Intravenous or oral ofloxacin
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Oral ofloxacin
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 58
Study: 6357257

Group type: EXPERIMENTAL
Intervention: Prazosin 1 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Prazosin 4 to 8 mg twice daily
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Hydralazine 50 to 100 mg twice daily
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combination of low doses of prazosin and hydralazine
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Prazosin and hydralazine
Number of subjects: 31
Study: 31037409

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 0
Study: 27755982

Group type: COMPARATOR
Intervention: Asenapine 5mg
Number of subjects: 164

Group type: COMPARATOR
Intervention: Asenapine 10mg
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo 5mg
Number of subjects: 164
Study: 26824082

Group type: EXPERIMENTAL
Intervention: Verbena officinalis Linn decoction (rinsing mouth with the decoction)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control group (brushing and flossing only)
Number of subjects: 260
Study: 25394502

Group type: EXPERIMENTAL
Intervention: Nebulized magnesium sulphate (MgSO4)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Standard treatment (nebulized salbutamol and ipratropium bromide with isotonic saline)
Number of subjects: 508
Study: 22849607

Group type: EXPERIMENTAL
Intervention: After-school exercise (n = 15)
Number of subjects: 29
Study: 19461006

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (2 soft-gel pills of 1 g each containing EPA and DHA)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (2 soft-gel pills, no active ingredients)
Number of subjects: 33
Study: 17461749

Group type: EXPERIMENTAL
Intervention: Media literacy curriculum
Number of subjects: 723
Study: 15657476

Group type: EXPERIMENTAL
Intervention: TCAI group (multinutrient supplement containing TCAIs)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: TCAI group
Number of subjects: 7
Study: 11697813

Group type: EXPERIMENTAL
Intervention: Short-chain fructo-oligosaccharides (sc-FOSs) 10 g/day
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sucrose (placebo)
Number of subjects: 11
Study: 9390050

Group type: EXPERIMENTAL
Intervention: 568 ml (one pint) of whole or reduced fat milk per day for 18 months
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (baseline average milk intake 150 ml)
Number of subjects: 82
Study: 8198917

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study: 3239338

Group type: EXPERIMENTAL
Intervention: IUD without tail (study group)
Number of subjects: 1183

Group type: COMPARATOR
Intervention: IUD with tail (control group)
Number of subjects: 1183

Group type: EXPERIMENTAL
Intervention: Both groups (pooled data)
Number of subjects: 1183
Study: 29909789

Group type: EXPERIMENTAL
Intervention: ICD-11PGD guideline
Number of subjects: 261

Group type: COMPARATOR
Intervention: PGDPLOS criteria
Number of subjects: 261
Study: 29282259

Group type: EXPERIMENTAL
Intervention: Exercise training (6-month weekly exercise program, 60 min, two times a week)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 83
Study: 27720650

Group type: EXPERIMENTAL
Intervention: Turmeric with black pepper
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nigella sativa
Number of subjects: 40
Study: 24682379

Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 7002

Group type: COMPARATOR
Intervention: Sulfonylureas
Number of subjects: 7002
Study: 22585232

Group type: EXPERIMENTAL
Intervention: THC 7.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: THC 15 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: THC (both doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 0
Study: 18560873

Group type: EXPERIMENTAL
Intervention: Betamethasone sodium phosphate 0.1% with neomycin sulphate 0.5% (Vista‐Methasone N)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Betamethasone sodium phosphate 0.1% (Vista‐Methasone)
Number of subjects: 45
Study: 17446010

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus melatonin (20 mg/day orally in the evening)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 370
Study: 15220952

Group type: EXPERIMENTAL
Intervention: Margarine enriched with alpha-linolenic acid (ALA) for 2 years
Number of subjects: 103

Group type: COMPARATOR
Intervention: Linoleic acid (LA) margarine for 2 years
Number of subjects: 103
Study: 11462311

Group type: EXPERIMENTAL
Intervention: Insulin therapy after a 12-week period with enhanced compliance to diet and oral therapy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Insulin therapy as soon as secondary failure was established
Number of subjects: 38

Group type: COMPARATOR
Intervention: Enhanced compliance to diet and oral therapy (control group)
Number of subjects: 38
Study: 9787691

Group type: COMPARATOR
Intervention: Depo-testosterone (to boys) or conjugated estrogens (to girls) administered in 3-month blocks, alternating with placebo, at 3 dose levels.
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (control group) administered in 3-month blocks, alternating with Depo-testosterone or conjugated estrogens.
Number of subjects: 55
Study: 7633988

Group type: EXPERIMENTAL
Intervention: Intravenous pentoxifylline infusion therapy, 600 mg twice daily for up to 21 days
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study: 1975522

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heparin in conjunction with aspirin and a thrombolytic agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium antagonists or antiarrhythmic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vasodilators
Number of subjects: 0
Study: 896123

Group type: EXPERIMENTAL
Intervention: Adriamycin (20‐25 mg/m2/day for three days each three weeks)
Number of subjects: 22
Study: 31188260

Group type: EXPERIMENTAL
Intervention: Operative treatment for intra-articular DRF based on patient factors such as younger age, clinically significant fracture displacement, normal activity level, and high-energy mechanisms.
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Surgeon factors recommending surgery, including practicing outside the United States.
Number of subjects: 224

Group type: COMPARATOR
Intervention: Treatment decisions rated by AUC recommendations.
Number of subjects: 224
Study: 27839722

Group type: EXPERIMENTAL
Intervention: rTMS (10 Hz)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study: 26037400

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation for 8 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 31
Study: 24274589

Group type: EXPERIMENTAL
Intervention: Endoscopic transluminal step-up approach
Number of subjects: 98

Group type: COMPARATOR
Intervention: Surgical step-up approach
Number of subjects: 98
Study: 21923016

Group type: EXPERIMENTAL
Intervention: Double-bundle ACL reconstruction
Number of subjects: 105

Group type: COMPARATOR
Intervention: Single-bundle ACL reconstruction
Number of subjects: 105
Study: 19140167

Group type: EXPERIMENTAL
Intervention: 5-[(123)I]IA administered intravenously at approximately 0.001 microg/kg (approximately 10 mCi)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High plasma-nicotine levels
Number of subjects: 12
Study: 17184672

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 16
Study: 15010644

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 10439

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 10439
Study: 11829098

Group type: EXPERIMENTAL
Intervention: Formoterol (Oxis Turbuhaler; 90 microg delivered dose; 120 microg metered dose)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Terbutaline (Bricanyl Turbuhaler; 10 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Formoterol (Oxis Turbuhaler; 90 microg)
Number of subjects: 48
Study: 10431650

Group type: EXPERIMENTAL
Intervention: Mechanic equipment operators
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Cranemen
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Container stevedores
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Hoistmen
Number of subjects: 341

Group type: COMPARATOR
Intervention: Control group (Electricians)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: All examined workers
Number of subjects: 341
Study: 8282977

Group type: EXPERIMENTAL
Intervention: Resistance training (12-exercise circuit, 3 sets of 8 repetitions at 75% of 1-RM), 3 times a week
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (sedentary, no exercise program)
Number of subjects: 25
Study: 2178939

Group type: EXPERIMENTAL
Intervention: Doxorubicin weekly for 6 weeks followed by no further treatment (short-term regimen)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Doxorubicin weekly for 6 weeks followed by monthly instillation for 2 years (long-term regimen)
Number of subjects: 146
Study: 72901

Group type: EXPERIMENTAL
Intervention: beta-blocker alone
Number of subjects: 7

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: beta-blocker plus indomethacin (100 mg daily)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: beta-blocker alone (last phase)
Number of subjects: 7
Study: 31562765

Group type: EXPERIMENTAL
Intervention: SGM-tailored Facebook intervention (POP)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Non-tailored intervention (TSP-SGM)
Number of subjects: 165
Study: 29338320

Group type: EXPERIMENTAL
Intervention: 12-month group medical clinic intervention
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: 12-month group medical clinic intervention stratified by >0.5% reduction in hemoglobin A1c
Number of subjects: 239

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 239

Group type: COMPARATOR
Intervention: usual care stratified by >0.5% reduction in hemoglobin A1c
Number of subjects: 239
Study: 28420471

Group type: EXPERIMENTAL
Intervention: Pv‐aCO2 combined with PLR directed therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Central venous pressure (CVP) directed therapy
Number of subjects: 80
Study: 25189089

Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone treatment
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Substance use disorder treatment (most commonly opioid agonist therapy)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Baseline pain severity
Number of subjects: 252
Study: 22092589

Group type: EXPERIMENTAL
Intervention: NobelActive(TM) implant
Number of subjects: 32

Group type: COMPARATOR
Intervention: Brånemark implant
Number of subjects: 32
Study: 17021415

Group type: EXPERIMENTAL
Intervention: Maximum Cobb angle technique
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tangent circles technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 30
Study: 14534586

Group type: EXPERIMENTAL
Intervention: Training on a small set of words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retention interval without sleep
Number of subjects: 0
Study: 10224729

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Stress Inoculation Training (SIT)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combined Treatment (PE-SIT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Wait-list Control (WL)
Number of subjects: 96
Study: 8722217

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol 60 mg/day
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol 200 mg/day
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol 15 mg/day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (all dosages)
Number of subjects: 31
Study: 1848679

Group type: EXPERIMENTAL
Intervention: Prophylactic ganciclovir (5 mg/kg IV twice daily for two weeks, then five times per week until day 120)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Observation alone (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prophylactic ganciclovir
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CMV-negative patients
Number of subjects: 40
Study: 6404377

Group type: EXPERIMENTAL
Intervention: Bedtime administration of intermediate acting insulin
Number of subjects: 6

Group type: COMPARATOR
Intervention: Conventional twice daily insulin regimen
Number of subjects: 6
Study: 31473600

Group type: EXPERIMENTAL
Intervention: Oxygen therapy at 6 L/min for 6-12 hours
Number of subjects: 5010

Group type: COMPARATOR
Intervention: Ambient air
Number of subjects: 5010

Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 5010
Study: 29296829

Group type: EXPERIMENTAL
Intervention: Andexanet alfa
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 26006195

Group type: COMPARATOR
Intervention: Lidocaine (L)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Lidocaine plus Benzydamine (LB)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Benzydamine (B)
Number of subjects: 118
Study: 23083421

Group type: EXPERIMENTAL
Intervention: Personalised insoles
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control insoles
Number of subjects: 38
Study: 20530054

Group type: EXPERIMENTAL
Intervention: 2 g fibrinogen concentrate
Number of subjects: 20

Group type: COMPARATOR
Intervention: No infusion (control group)
Number of subjects: 20
Study: 19850684

Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated equine estrogens (CEE) daily
Number of subjects: 886

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 886
Study: 17178700

Group type: EXPERIMENTAL
Intervention: Oral alpha-lipoic acid, 600 mg twice daily for 4 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (normal glucose tolerance)
Number of subjects: 12
Study: 12932748

Group type: COMPARATOR
Intervention: Growth Hormone (GH) treatment (Genotropin, Pharmacia) starting at 0.8 IU for one month, then 1.6 IU for 5 months, followed by individual titration to normal levels for age.
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo treatment.
Number of subjects: 17
Study: 11101059

Group type: EXPERIMENTAL
Intervention: Twice-daily stavudine (40 mg) plus once-daily didanosine (400 mg) and nevirapine (400 mg)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Twice-daily stavudine (40 mg) plus twice-daily didanosine (200 mg) and nevirapine (200 mg)
Number of subjects: 94
Study: 8985029

Group type: EXPERIMENTAL
Intervention: Radiotherapy and razoxane (150 mg/m2 daily during radiotherapy, starting 5 days before first irradiation)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Radiotherapy and razoxane
Number of subjects: 130
Study: 1451518

Group type: EXPERIMENTAL
Intervention: Copper-plated uterine cavity-shaped IUD (UCDcu)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uterine cavity-shaped stainless steel IUD (UCD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both IUDs (UCDcu and UCD)
Number of subjects: 0
Study: 6372024

Group type: EXPERIMENTAL
Intervention: Perioperative antibiotics
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 30802762

Group type: EXPERIMENTAL
Intervention: Soccer-specific fatigue protocol
Number of subjects: 10
Study: 29454318

Group type: EXPERIMENTAL
Intervention: Points-based physical activity (PBPA; 30 'PA points'•week‐1)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (CONT; continue habitual inactive lifestyle)
Number of subjects: 76
Study: 26810282

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with HDM allergen extract
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 24971785

Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate alone
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate and Metformin
Number of subjects: 56
Study: 21782542

Group type: EXPERIMENTAL
Intervention: Bilateral high-frequency rTMS (20 Hz) administered daily for 4 weeks (total of 20 treatments)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract)
Number of subjects: 25
Study: 21149920

Group type: EXPERIMENTAL
Intervention: HBsAg quantification
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Pegylated interferon treatment
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Validation group
Number of subjects: 289
Study: 16979255

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 24

Group type: COMPARATOR
Intervention: NPH
Number of subjects: 24
Study: 15692345

Group type: EXPERIMENTAL
Intervention: Le Fort III osteotomy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 31
Study: 12382459

Group type: EXPERIMENTAL
Intervention: APN intervention
Number of subjects: 32

Group type: COMPARATOR
Intervention: No APN intervention (Control)
Number of subjects: 32
Study: 9923817

Group type: EXPERIMENTAL
Intervention: 200 mg dolasetron daily plus 300 mg cimetidine four times daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 200 mg dolasetron daily plus 600 mg rifampin daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: 200 mg dolasetron daily (control)
Number of subjects: 18
Study: 7578795

Group type: EXPERIMENTAL
Intervention: Barrier membrane alone
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Bone allograft with barrier membrane
Number of subjects: 19
Study: 2254674

Group type: EXPERIMENTAL
Intervention: Ketanserin (20‐40 mg three times a day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 40
Study: 7000089

Group type: EXPERIMENTAL
Intervention: Colestipol hydrochloride (5 g X 3)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Colestipol (15 g daily) divided into 1, 2 or 3 daily doses
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Colestipol hydrochloride (15 g daily)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Colestipol treatment
Number of subjects: 22
Study: 31948475

Group type: EXPERIMENTAL
Intervention: Jianpishengsui (JPSS) herbal formula cream, 15g orally, twice a day from day 6 to day 20 during chemotherapy.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, twice a day from day 6 to day 20 during chemotherapy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Jianpishengsui (JPSS) herbal formula cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Jianpishengsui (JPSS) herbal formula cream and Placebo
Number of subjects: 0
Study: 31684903

Group type: EXPERIMENTAL
Intervention: Nurse-led guided participation discharge intervention (three structured 30- to 60-min GP sessions and one follow-up phone call)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nurse-led guided participation discharge intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study: 28806820

Group type: EXPERIMENTAL
Intervention: Didactic training
Number of subjects: 17

Group type: COMPARATOR
Intervention: Computer-based self-learning
Number of subjects: 17
Study: 25814356

Group type: EXPERIMENTAL
Intervention: Invasive strategy (PCI)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Conservative strategy (ischemia-guided)
Number of subjects: 216
Study: 23968283

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation over the left supramarginal gyrus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (control group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual memory control task
Number of subjects: 0
Study: 21853543

Group type: EXPERIMENTAL
Intervention: T2-hyperintensities on brain MRI
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (children without NF1)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: T2-hyperintensities on brain MRI in children aged 2-7 years
Number of subjects: 162
Study: 20168020

Group type: EXPERIMENTAL
Intervention: Promotora intervention (community health worker) for 9 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98